These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 8124689)

  • 1. Colon adenocarcinoma cells inhibit anti-CD3-activated killer cell induction.
    Hoskin DW; Reynolds T; Blay J
    Cancer Immunol Immunother; 1994 Mar; 38(3):201-7. PubMed ID: 8124689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human lymphokine-activated killer cells augment immunotherapy of human colon carcinoma xenografts with monoclonal antibody D612.
    Pendurthi TK; Schlom J; Primus FJ
    J Immunother (1991); 1991 Feb; 10(1):2-12. PubMed ID: 2012797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of cellular immunotherapies and anti-CD3 in the treatment of MCA-38-LD experimental hepatic metastases in C57BL/6 mice.
    Gallinger S; Hoskin DW; Mullen JB; Wong AH; Roder JC
    Cancer Res; 1990 Apr; 50(8):2476-80. PubMed ID: 2138507
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of interleukin-1 alpha on the in vitro activation of tumor-draining lymph node cells for adoptive immunotherapy.
    Hammel JM; Tuck MK; Hain JM; Chang AE; Sondak VK
    J Immunother Emphasis Tumor Immunol; 1994 Jul; 16(1):1-12. PubMed ID: 8081555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of suppression of lymphokine-activated killer cells by transforming growth factor-beta in ovarian carcinoma ascitic fluid requires interleukin-2 combined with anti-CD3 antibody.
    Hirte HW; Clark DA; O'Connell G; Rusthoven J; Mazurka J
    Cell Immunol; 1992 Jun; 142(1):207-16. PubMed ID: 1534038
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of anti-CD3/anti-CD28/interleukin-2 stimulation of mononuclear cells on transforming growth factor beta inhibition of lymphokine-activated killer cell generation.
    Koberda J; Grimm EA; Moser RP
    J Cancer Res Clin Oncol; 1993; 119(3):131-6. PubMed ID: 8380285
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel adenovirus expressing human 4-1BB ligand enhances antitumor immunity.
    Yoshida H; Katayose Y; Unno M; Suzuki M; Kodama H; Takemura S; Asano R; Hayashi H; Yamamoto K; Matsuno S; Kudo T
    Cancer Immunol Immunother; 2003 Feb; 52(2):97-106. PubMed ID: 12594573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allogeneic cell-mediated immunotherapy for eradication of minimal residual disease: comparison of T-cell and IL-2 activated killer (LAK) cell-mediated adoptive immunotherapy in murine models.
    Vourka-Karussis U; Ackerstein A; Pugatsch T; Slavin S
    Exp Hematol; 1999 Mar; 27(3):461-9. PubMed ID: 10089908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysregulation of telomerase activity and expression in lymphokine-activated killer cells from advanced cancer patients: possible involvement in cancer-associated immunosuppression mechanism.
    Minami K; Yamaguchi Y; Yoshida K; Quan CP; Toge T
    Oncol Rep; 2001; 8(3):649-53. PubMed ID: 11295096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced human lymphokine-activated killer cell function after brief exposure to granulocyte-macrophage-colony stimulating factor.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Beroukas C; Stathopoulos GP; Papamichail M
    Cancer; 1995 Oct; 76(7):1253-60. PubMed ID: 8630906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphokine-activated killer cell induction in tumor-infiltrating leukocytes from colon cancer patients.
    Staren ED; Economou SG; Harris JE; Braun DP
    Cancer; 1989 Dec; 64(11):2238-42. PubMed ID: 2804913
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful combination immunotherapy for the generation in vivo of antitumor activity with anti-CD3, interleukin 2, and tumor necrosis factor alpha.
    Yang SC; Fry KD; Grimm EA; Roth JA
    Arch Surg; 1990 Feb; 125(2):220-5. PubMed ID: 2137327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of anti-CD3 antibody on the generation of interleukin-2-activated lymphocytes from tumor tissues of gastrointestinal cancer.
    Ohta T; Kikuchi H; Ogata H; Iwata K; Yoshida K; Katayama K; Watanabe H
    Cancer; 1992 Aug; 70(4):741-8. PubMed ID: 1386555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of cancer immunotherapy with indomethacin and interleukin-2 on murine hemopoietic stem cells.
    Saarloos MN; Khoo NK; Lala PK
    Cancer Res; 1992 Dec; 52(23):6452-62. PubMed ID: 1423293
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of surgery and chemotherapy on cellular immunity in pancreatic carcinoma patients in view of an integration of standard cancer treatment with immunotherapy.
    Bellone G; Novarino A; Vizio B; Brondino G; Addeo A; Prati A; Giacobino A; Campra D; Fronda GR; Ciuffreda L
    Int J Oncol; 2009 Jun; 34(6):1701-15. PubMed ID: 19424589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synergistic effect of Nocardia rubra cell wall skeleton and recombinant interleukin 2 for in vivo induction of lymphokine-activated killer cells.
    Miyazaki K; Yasumoto K; Yano T; Matsuzaki G; Sugimachi K; Nomoto K
    Cancer Res; 1991 Oct; 51(19):5261-5. PubMed ID: 1833049
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor effect of human lymphocytes and interleukin-2.
    Anwer F; Mesri M; Rees RC; Kazmi SU
    J Pak Med Assoc; 1993 Mar; 43(3):45-9. PubMed ID: 8326667
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
    Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
    J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lymphokine-activated killer-cell-mediated killing of WiDr colon carcinoma cells is inhibited by K562 erythroleukemia cells.
    Dullens HF; Wind JC; Maas RA; Bernsen MR; Vulto IM; Rademakers LH; Den Otter W
    Int Immunol; 1991 Oct; 3(10):959-64. PubMed ID: 1756146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human lymphokine activated killer (LAK) cells suppress generation of allospecific cytotoxic T cells: implications for use of LAK cells to prevent graft-versus-host disease in allogeneic bone marrow transplantation.
    Uberti J; Martilotti F; Chou TH; Kaplan J
    Blood; 1992 Jan; 79(1):261-8. PubMed ID: 1370206
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.